Chris

[Dong Nguyen @DongNguyeb]

Regarding urinary function in EPIC-26:

5-year results: 14/29 (48%) in the RP arm vs. 3/36 (8%) in the SBRT arm.

But don't let the number fool you into overlooking the nature of how they reported it.
The authors chose a single question about the number of pads needed per day to give impression .
Other urinary questions in EPIC-26 were reported, but only as secondary endpoints.

If the results were reported in full, the picture would be different:
RP is worse for urinary incontinence, while SBRT is worse for obstructive symptoms.
But overall, the degree of urinary bother between the two arms shows no statistically significant difference.

[Chris @Cwechris]

@rewcastle_john @DrewMoghanaki @SJFrankMD @DrSpratticus @uroegg @dr_coops @SFreedlandMD @AmarUKishan @fcounago @DrAndrewLoblaw @NehaVapiwala @drjefstathiou Agree curves may split at 20y which will be good to help inform patient discussions, but think cumulative pcsm should be used to counsel patients rather than deaths per time period.

[Chris @Cwechris]

@rewcastle_john @DrewMoghanaki @SJFrankMD @DrSpratticus @uroegg @dr_coops @SFreedlandMD @AmarUKishan @fcounago @DrAndrewLoblaw @NehaVapiwala @drjefstathiou How did you arrive at 12 vs 16 deaths = 7 times higher?

[Chris @Cwechris]

@dschan02 @Aedrareforged Blizzard loves their recurrent writing tropes like academic physicists love FLASH.

[Chris @Cwechris]

@RSanchez_Salas There are some nunbers available here: https://t.co/c0VVIdejG5

However just like the recent london study it is retrospective and also lacks toxicity grading as far as I can see. We should wait for the results of the several RCTs in this space before the next twitter debate.

[Chris @Cwechris]

@DongNguyeb @DongNguyen614x @DrSpratticus I think the area of contention here is that prescribed D95% to CTV was 40Gy in PACE B which doesnt seem to be the case in GU005. With hotspots dose would end up much higher. I dont have access to the GU005 protocol though so correct me if I am wrong.

[Chris @Cwechris]

@jryckman3 What do you make of this exclusion of patients with "salvage treatment"?

[Chris @Cwechris]

@IP_London @EUplatinum @AJWLight @LondonProstate1 @TaimurShah Amazing work. However could a little bit more be elaborated on the patients receiving salvage treatment who were excluded from the study?

[OncoAlert @OncoAlert]

Day THREE of #ESTRO26 Coverage by OncoAlert 🚨
Metastases-directed treatment in Patients with Oligometastatic Breast Cancer: Results from the OLIGOMA-trial (ARO-2021-09, NCT04495309)
Presented by David Krug 🇩🇪
#RadOnc ☢️

The OLIGOMA-trial is a randomized controlled trial studying the role of local ablative radiotherapy in patients with oligometastatic breast cancer (≤ 5 lesions) receiving standard systemic therapy. 87 patients were enrolled at 31 sites in Germany and Austria, the study was closed early due to slow accrual. Both co-primary endpoints were positive: Progression-free survival was significantly improved (HR 0.48) while maintaining non-inferiority for quality of life 12 weeks after randomization.

@DavidKrugMD
#RadOnc
@ESTRO_RT
@yasemin09896924
@LindaMrissa
@christian_roenn
@Valeriadionisi
@gerryhanna
@clchiang_hk
@mtugceyilmaz
@B_Tomasik
@gmpetrianni
@CiroFranzese1
@Atem84
@piet_ost
@brachyexpert
@BlanceS90
@The_PT_Explorer
@BarbaraJereczek
@Mat_Guc
@ZilliThomas
@AnnaKirby17
@PBlanchardMD
@achoud72

Pinging OA faculty
@MKnoll_MD
@_ShankarSiva
@Icro_Meattini
@seanmmcbride
@NiuSanford
@nataliagandur
@acampsmalea
@to_be_elizabeth

[OncoAlert @OncoAlert]

Day TWO of #ESTRO26 Coverage by OncoAlert 🚨
Optimizing oligometastatic disease management with circulating tumor DNA: a correlative analysis from the phase II randomized EXTEND trial Presented by Alexander Sherry 🇺🇸
#RadOnc ☢️

The current definition of oligometastasis entails lesion counting. We hypothesized that circulating tumor DNA (ctDNA) would improve stratification and predict responses to metastasis-directed therapy (MDT). We profiled ctDNA among 237 patients enrolled on the EXTEND trial. We found ctDNA was strongly associated with multiple clinical outcomes, as well as ctDNA clearance following enrollment. These data suggest that ctDNA holds strong promise for transforming the management of patients with oligometastatic cancers.

@AlexSherryMD @ChadTangMD @ebludmir @PavlosMsaouel @MDAndersonNews

@ESTRO_RT
@yasemin09896924
@LindaMrissa
@christian_roenn
@Valeriadionisi
@gerryhanna
@clchiang_hk
@mtugceyilmaz
@B_Tomasik
@gmpetrianni
@CiroFranzese1
@Atem84
@piet_ost
@brachyexpert
@BlanceS90
@The_PT_Explorer
@BarbaraJereczek
@Mat_Guc
@ZilliThomas
@AnnaKirby17
@PBlanchardMD
@achoud72

Pinging OA faculty
@MKnoll_MD
@_ShankarSiva
@Icro_Meattini
@seanmmcbride
@NiuSanford
@nataliagandur
@acampsmalea
@to_be_elizabeth

[Chris @Cwechris]

@5_utr Think the graphic slightly misrepresents the data, these are the actual ones from the appendix

[Erman Akkus @Erman_Akkus]

Neoadjuvant Single-Cycle Pembrolizumab for Stage I-III MMR-Deficient Colon Cancer: The RESET-C Trial | Journal of Clinical Oncology @OncoAlert https://t.co/wSUbV70vg0

[Chris @Cwechris]

@tompowles1 If 57.1% had path CR, how will you identify these patients? Until then the neoadjuvant EV-P approach seems the right direction? Also, pt cohort fit enough to receive 9 cycles of EV-P should also be offered 3x NA chemo prior to chemoRT in control?

[Just Treatment 💊 @JustTreatment]

WATCH: @andrewmeyerson - a junior doctor from the US - shares his love for the #NHS & why he's striking to save its future.

As patients we stand united with NHS junior doctors as they begin a historic 5-day strike for #PayRestoration. Solidarity! ✊

#JuniorDoctorsStrike